Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD

19.375  +0.68 (+3.61%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to ADMA. ADMA was compared to 553 industry peers in the Biotechnology industry. ADMA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ADMA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes ADMA very considerable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 40.50%, ADMA belongs to the top of the industry, outperforming 99.10% of the companies in the same industry.
ADMA's Return On Equity of 55.37% is amongst the best of the industry. ADMA outperforms 98.73% of its industry peers.
The Return On Invested Capital of ADMA (26.28%) is better than 98.73% of its industry peers.
Industry RankSector Rank
ROA 40.5%
ROE 55.37%
ROIC 26.28%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

Looking at the Profit Margin, with a value of 45.01%, ADMA belongs to the top of the industry, outperforming 98.92% of the companies in the same industry.
ADMA has a better Operating Margin (33.10%) than 97.83% of its industry peers.
ADMA's Gross Margin of 52.58% is fine compared to the rest of the industry. ADMA outperforms 77.58% of its industry peers.
In the last couple of years the Gross Margin of ADMA has grown nicely.
Industry RankSector Rank
OM 33.1%
PM (TTM) 45.01%
GM 52.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ADMA has more shares outstanding than it did 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ADMA has an improved debt to assets ratio.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ADMA has an Altman-Z score of 21.34. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ADMA (21.34) is better than 94.58% of its industry peers.
The Debt to FCF ratio of ADMA is 0.80, which is an excellent value as it means it would take ADMA, only 0.80 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of ADMA (0.80) is better than 95.48% of its industry peers.
ADMA has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
ADMA has a worse Debt to Equity ratio (0.19) than 69.80% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.8
Altman-Z 21.34
ROIC/WACC2.67
WACC9.84%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.58 indicates that ADMA has no problem at all paying its short term obligations.
ADMA's Current ratio of 6.58 is fine compared to the rest of the industry. ADMA outperforms 64.01% of its industry peers.
A Quick Ratio of 3.36 indicates that ADMA has no problem at all paying its short term obligations.
ADMA's Quick ratio of 3.36 is in line compared to the rest of the industry. ADMA outperforms 40.51% of its industry peers.
Industry RankSector Rank
Current Ratio 6.58
Quick Ratio 3.36
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 2750.00% over the past year.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 62.23%.
ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%

3.2 Future

Based on estimates for the next years, ADMA will show a very strong growth in Earnings Per Share. The EPS will grow by 33.77% on average per year.
ADMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.03% yearly.
EPS Next Y23.76%
EPS Next 2Y37.99%
EPS Next 3Y37.7%
EPS Next 5Y33.77%
Revenue Next Year20.15%
Revenue Next 2Y23.19%
Revenue Next 3Y25.1%
Revenue Next 5Y21.03%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 36.56, the valuation of ADMA can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.49% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.25. ADMA is valued slightly more expensive when compared to this.
ADMA is valuated rather expensively with a Price/Forward Earnings ratio of 20.35.
Based on the Price/Forward Earnings ratio, ADMA is valued cheaper than 92.95% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ADMA to the average of the S&P500 Index (36.80), we can say ADMA is valued slightly cheaper.
Industry RankSector Rank
PE 36.56
Fwd PE 20.35
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.49% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 92.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 51.23
EV/EBITDA 27.92
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 37.70% in the coming years.
PEG (NY)1.54
PEG (5Y)N/A
EPS Next 2Y37.99%
EPS Next 3Y37.7%

More info and screens

0

5. Dividend

5.1 Amount

ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADMA BIOLOGICS INC

NASDAQ:ADMA (8/1/2025, 3:53:08 PM)

19.375

+0.68 (+3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06
Inst Owners86.66%
Inst Owner Change0.61%
Ins Owners2.37%
Ins Owner Change2%
Market Cap4.63B
Analysts82
Price Target30.08 (55.25%)
Short Float %6.32%
Short Ratio5.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.83%
Min EPS beat(2)-31.17%
Max EPS beat(2)-8.5%
EPS beat(4)2
Avg EPS beat(4)8.19%
Min EPS beat(4)-31.17%
Max EPS beat(4)59.31%
EPS beat(8)4
Avg EPS beat(8)-15.66%
EPS beat(12)7
Avg EPS beat(12)-6.3%
EPS beat(16)10
Avg EPS beat(16)-4.09%
Revenue beat(2)1
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)2.16%
Revenue beat(4)3
Avg Revenue beat(4)7.87%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)21.61%
Revenue beat(8)7
Avg Revenue beat(8)6.02%
Revenue beat(12)11
Avg Revenue beat(12)6.72%
Revenue beat(16)15
Avg Revenue beat(16)7.22%
PT rev (1m)0%
PT rev (3m)16.69%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-19.23%
EPS NY rev (1m)-8.77%
EPS NY rev (3m)-14.55%
Revenue NQ rev (1m)-0.35%
Revenue NQ rev (3m)1.12%
Revenue NY rev (1m)-1.56%
Revenue NY rev (3m)2.51%
Valuation
Industry RankSector Rank
PE 36.56
Fwd PE 20.35
P/S 10.07
P/FCF 51.23
P/OCF 45.7
P/B 12.39
P/tB 12.52
EV/EBITDA 27.92
EPS(TTM)0.53
EY2.74%
EPS(NY)0.95
Fwd EY4.91%
FCF(TTM)0.38
FCFY1.95%
OCF(TTM)0.42
OCFY2.19%
SpS1.92
BVpS1.56
TBVpS1.55
PEG (NY)1.54
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 40.5%
ROE 55.37%
ROCE 33.26%
ROIC 26.28%
ROICexc 31.16%
ROICexgc 31.49%
OM 33.1%
PM (TTM) 45.01%
GM 52.58%
FCFM 19.65%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.8
Debt/EBITDA 0.45
Cap/Depr 138.39%
Cap/Sales 2.38%
Interest Coverage 11.85
Cash Conversion 63.28%
Profit Quality 43.66%
Current Ratio 6.58
Quick Ratio 3.36
Altman-Z 21.34
F-Score7
WACC9.84%
ROIC/WACC2.67
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y23.76%
EPS Next 2Y37.99%
EPS Next 3Y37.7%
EPS Next 5Y33.77%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%
Revenue Next Year20.15%
Revenue Next 2Y23.19%
Revenue Next 3Y25.1%
Revenue Next 5Y21.03%
EBIT growth 1Y243.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.1%
EBIT Next 3Y43.62%
EBIT Next 5Y38.62%
FCF growth 1Y247.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y309.9%
OCF growth 3YN/A
OCF growth 5YN/A